These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20713864)

  • 21. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
    Furman WL; Navid F; Daw NC; McCarville MB; McGregor LM; Spunt SL; Rodriguez-Galindo C; Panetta JC; Crews KR; Wu J; Gajjar AJ; Houghton PJ; Santana VM; Stewart CF
    J Clin Oncol; 2009 Sep; 27(27):4599-604. PubMed ID: 19687340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
    Chien AJ; Illi JA; Ko AH; Korn WM; Fong L; Chen LM; Kashani-Sabet M; Ryan CJ; Rosenberg JE; Dubey S; Small EJ; Jahan TM; Hylton NM; Yeh BM; Huang Y; Koch KM; Moasser MM
    Clin Cancer Res; 2009 Sep; 15(17):5569-75. PubMed ID: 19706807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
    Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
    Kieran MW; Packer RJ; Onar A; Blaney SM; Phillips P; Pollack IF; Geyer JR; Gururangan S; Banerjee A; Goldman S; Turner CD; Belasco JB; Broniscer A; Zhu Y; Frank E; Kirschmeier P; Statkevich P; Yver A; Boyett JM; Kun LE
    J Clin Oncol; 2007 Jul; 25(21):3137-43. PubMed ID: 17634493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).
    DeWire M; Fouladi M; Turner DC; Wetmore C; Hawkins C; Jacobs C; Yuan Y; Liu D; Goldman S; Fisher P; Rytting M; Bouffet E; Khakoo Y; Hwang EI; Foreman N; Stewart CF; Gilbert MR; Gilbertson R; Gajjar A
    J Neurooncol; 2015 May; 123(1):85-91. PubMed ID: 25859842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
    Crown J; Kennedy MJ; Tresca P; Marty M; Espie M; Burris HA; DeSilvio M; Lau MR; Kothari D; Koch KM; Diéras V
    Ann Oncol; 2013 Aug; 24(8):2005-11. PubMed ID: 23878115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.
    Packer RJ; Rood BR; Turner DC; Stewart CF; Fisher M; Smith C; Young-Pouissant T; Goldman S; Lulla R; Banerjee A; Pollack I; Kun L; Onar-Thomas A; Wu S; Boyett JM; Fouladi M
    J Neurooncol; 2015 Jan; 121(1):217-24. PubMed ID: 25407389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects.
    Wang MN; Kuang Y; Gong LY; Hua Y; Pei Q; Guo CX; Cao Y; Huang J; Yang GP
    Invest New Drugs; 2020 Dec; 38(6):1826-1835. PubMed ID: 32535812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
    Daw NC; Furman WL; Stewart CF; Iacono LC; Krailo M; Bernstein ML; Dancey JE; Speights RA; Blaney SM; Croop JM; Reaman GH; Adamson PC;
    J Clin Oncol; 2005 Sep; 23(25):6172-80. PubMed ID: 16135484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
    Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
    Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial.
    Fangusaro J; Mitchell DA; Kocak M; Robinson GW; Baxter PA; Hwang EI; Huang J; Onar-Thomas A; Dunkel IJ; Fouladi M; Warren KE
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28756. PubMed ID: 33025730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
    Broniscer A; Baker JN; Tagen M; Onar-Thomas A; Gilbertson RJ; Davidoff AM; Pai Panandiker AS; Leung W; Chin TK; Stewart CF; Kocak M; Rowland C; Merchant TE; Kaste SC; Gajjar A
    J Clin Oncol; 2010 Nov; 28(31):4762-8. PubMed ID: 20921456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
    Geyer JR; Stewart CF; Kocak M; Broniscer A; Phillips P; Douglas JG; Blaney SM; Packer RJ; Gururangan S; Banerjee A; Kieran MW; Kun LE; Gilbertson RJ; Boyett JM
    Eur J Cancer; 2010 Dec; 46(18):3287-93. PubMed ID: 20708924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
    Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
    Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
    Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
    de Souza JA; Davis DW; Zhang Y; Khattri A; Seiwert TY; Aktolga S; Wong SJ; Kozloff MF; Nattam S; Lingen MW; Kunnavakkam R; Stenson KM; Blair EA; Bozeman J; Dancey JE; Vokes EE; Cohen EE
    Clin Cancer Res; 2012 Apr; 18(8):2336-43. PubMed ID: 22371453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.